Regulation FD Disclosure (Form 8-K)

Item 7.01. Regulation FD Disclosure.

On April 2, 2025, Novavax, Inc. (the "Company") issued the following statement:

Novavax can confirm that April 1, 2025, was the U.S. Food and Drug Administration ("FDA")'s Prescription Drug User Fee Act date for our Biologics License Application ("BLA") seeking the approval of our COVID-19 Vaccine. As of Tuesday, April 1, we had responded to all of the FDA's information requests and we believe that our BLA is ready for approval. As of today, we continue to wait on action from the agency and have not yet received an official decision from the U.S. FDA.

Our application included robust Phase 3 clinical trial data that showed our vaccine is safe and effective for the prevention of COVID-19.We are confident our well-tolerated vaccine represents an attractive alternative to mRNA COVID-19 vaccines for the U.S.

The information in Item 7.01 of this Current Report on Form 8-K, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.